Search

Desloratadine

Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

Ferrous sulfate anhydrous

[A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells.

Melatonin

) but outside the blood-brain barrier. … In mammals, melatonin is produced by the pineal gland.

Ulipristal

The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. … Nevertheless, current and ongoing research into the agent's mechanism of action as an emergency contraceptive continue to provide potentially plausible evidence that ulipristal may, in fact, elicit activity

Reviparin

[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.

(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER

Ecamsule

Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal. … The company got approval for those products through a new drug application process.

Nelarabine

[A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879]

Safrazine

Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

Belinostat

Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. … It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.